Metrorrhagia Market
Key Highlights
- As per Davis et al. (2022), The prevalence of abnormal uterine bleeding among reproductive-aged women internationally is estimated to be between 3% to 30%, with a higher incidence occurring around menarche and perimenopause. Many studies are limited to heavy menstrual bleeding (HMB), but when irregular and intermenstrual bleeding are considered, the prevalence rises to 35% or greater.
- Metrorrhagia epidemiology is segmented as Metrorrhagia Prevalence, Metrorrhagia Type-specific Prevalence, Metrorrhagia Diagnosed and Treatable Cases in the Metrorrhagia market report.
Request to unlock CAGR of Metrorrhagia Market
DelveInsight’s “Metrorrhagia Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Metrorrhagia , historical and forecasted epidemiology as well as the Metrorrhagia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Metrorrhagia market report provides current treatment practices, emerging drugs, Metrorrhagia market share of the individual therapies, and current and forecasted Metrorrhagia market size from 2019 to 2032, segmented by seven major markets. The report also covers current Metrorrhagia treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study period: 2019–2032
Metrorrhagia Market: Understanding and Treatment Algorithm
The DelveInsight’s Metrorrhagia market report gives a thorough understanding of Metrorrhagia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Metrorrhagia is abnormal bleeding between regular menstrual periods. Metrorrhagia, now commonly called intermenstrual bleeding, is vaginal bleeding that occurs at irregular intervals and is not associated with the menstrual cycle. While the blood comes from the uterus as it does during menstruation, the bleeding does not represent a normal period. There are several causes of metrorrhagia, some of which are harmless. In other cases, metrorrhagia can be a sign of a more serious condition.
Common causes of metrorrhagia include pregnancy, use of certain contraceptives (especially Depo-Provera) and intrauterine devices, and STIs. Other causes include coagulation disorders, genital trauma, neoplasms, and infections such as tuberculosis. Metrorrhagia can also be a sign of an underlying health conditions like uterine inflammation (endometritis), cervical inflammation (cervicitis), etc. While some of the conditions are considered benign, others can have serious consequences if left untreated. Metrorrhagia is specific to vaginal bleeding that happens during the month other than when someone is having or would expect to have their menstrual period. Ovulatory DUB, causes irregular shedding of the uterine lining and break-through bleeding. Some evidence has associated ovulatory DUB with more fragile blood vessels in the uterus. It may represent a possible endocrine dysfunction, resulting in menorrhagia or metrorrhagia. This causes irregular shedding of the uterine lining and break-through bleeding.
Anovulatory DUB, in such cases, women do not properly develop and release a mature egg. When this happens, the corpus luteum, which is a mound of tissue that produces progesterone, does not form. As a result, estrogen is produced continuously, causing an overgrowth of the uterus lining. The period is delayed in such cases, and when it occurs menstruation can be very heavy and prolonged.
Metrorrhagia Diagnosis
Diagnosis of Metrorrhagia requires thorough patient’s symptoms screening and blood tests to confirm the metrorrhagia.
Metrorrhagia Treatment
Treatment of abnormal uterine bleeding varies, depending on the cause. For example, if fibroids are found they need to be removed either by myomectomy or hysterectomy, and if cancer is found the appropriate treatment needs to be given. If no cause is found then the patient is labeled as having dysfunctional uterine bleeding [DUB], diagnosis by exclusion. If this type of bleeding is suspected but treatment fails, other causes should be investigated. The goals in treatment of dysfunctional uterine bleeding are to control bleeding, prevent recurrences, and preserve fertility if the patient requires it. The choice of treatment depends on whether bleeding is acute or chronic.
Metrorrhagia Epidemiology
The Metrorrhagia epidemiology section provides insights into historical and current Metrorrhagia patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Metrorrhagia report also provides the diagnosed patient pool, their trends and assumptions undertaken.
Key findings
- As per Davis et al. (2022), The prevalence of abnormal uterine bleeding among reproductive-aged women internationally is estimated to be between 3% to 30%, with a higher incidence occurring around menarche and perimenopause. Many studies are limited to heavy menstrual bleeding (HMB), but when irregular and intermenstrual bleeding are considered, the prevalence rises to 35% or greater.
- The Metrorrhagia epidemiology covered in the report provides historical as well as forecasted Metrorrhagia epidemiology [segmented as Prevalence of Metrorrhagia, Type-specific Prevalence of Metrorrhagia, Diagnosed and Treatable Cases of Metrorrhagia] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Country-wise Metrorrhagia Epidemiology
The epidemiology segment also provides the Metrorrhagia epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Metrorrhagia Drug Chapters
The drug chapter segment of the Metrorrhagia report encloses the detailed analysis of Metrorrhagia marketed drugs and late-stage (Phase III and Phase II) Metrorrhagia pipeline drugs. It also helps understand the Metrorrhagia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Metrorrhagia drugs
The report details the emerging Metrorrhagia therapies under the late and mid-stage of development for Metrorrhagia treatment.
Metrorrhagia Market Outlook
The Metrorrhagia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Metrorrhagia market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Metrorrhagia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Metrorrhagia market in 7MM is expected to witness a major change in the study period 2019–2032.
Key findings
This section includes a glimpse of the Metrorrhagia market in 7MM.
The United States: Metrorrhagia Market Outlook
This section provides the total Metrorrhagia market size and market size by therapies in the United States.
EU4 and the United Kingdom Countries: Metrorrhagia Market Outlook
The total Metrorrhagia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan: Metrorrhagia Market Outlook
The total Metrorrhagia market size and market size by therapies in Japan is also mentioned.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
Metrorrhagia Cases |
XXXX Cases in 2022 |
|
Key Companies |
AbbVie, Takeda, MyovantSciences GmbH and Many Others. |
Metrorrhagia Drug Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Metrorrhagia market or expected to get launched in the market during the study period 2019–2032. The analysis covers Metrorrhagia market uptake by drugs, patient uptake by therapies, and sales of each drug.
This will help in understanding the Metrorrhagia drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Metrorrhagia Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Metrorrhagia ’ key players involved in developing targeted therapeutics.
Metrorrhagia Clinical Trial Development Activities
The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Metrorrhagia emerging therapies.
Metrorrhagia Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Metrorrhagia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Metrorrhagia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform competitive and market intelligence analysis of the Metrorrhagia market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Metrorrhagia Market Report
- Descriptive overview of Metrorrhagia disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
- Comprehensive insight into the Metrorrhagia epidemiology and forecasts in the 7MM
- An all-inclusive account of both the current and emerging therapies for Metrorrhagia along with the assessment of new therapies, expected to have an impact on the current treatment landscape
- Exhaustive analysis of the Metrorrhagia market; historical and forecasted covering drug outreach in the 7MM
- Detailed patient based market forecasting determines the trends shaping and driving the global Metrorrhagia market
Metrorrhagia Market Report Highlights
- In the coming years, the Metrorrhagia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Metrorrhagia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing Metrorrhagia therapies. The launch of emerging therapies will significantly impact the Metrorrhagia market
- A better understanding of Metrorrhagia pathogenesis will also contribute to the development of novel therapeutics for Metrorrhagia
- Our in-depth analysis of the Metrorrhagia pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Metrorrhagia clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metrorrhagia Report Insights
- Patient Based Market Forecasting
- Therapeutic approaches
- Metrorrhagia pipeline analysis
- Metrorrhagia market size and trends
- Metrorrhagia market opportunities
- Impact of upcoming therapies
Metrorrhagia Report Key Strengths
- 11 years’ forecast
- 7MM coverage
- Metrorrhagia epidemiology segmentation
- Key cross competition
- KOL views
- Metrorrhagia drugs uptake
Metrorrhagia Report Assessment
- Current treatment practices
- Unmet needs
- Metrorrhagia pipeline product profiles
- Metrorrhagia market attractiveness
Key Questions
Metrorrhagia market insights:
- What would be the Metrorrhagia market growth till 2032, and what will be the resultant market size in 2032?
- What was the Metrorrhagia drug class share (in percentage) distribution in 2019, and how would it look in 2032?
- What would be the Metrorrhagia total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the key findings of the market across 7MM, and which country will have the largest Metrorrhagia market size during the forecast period (2019–2032)
- How would the unmet needs affect the Metrorrhagia market dynamics and subsequent analysis of the associated trends?
Metrorrhagia Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Metrorrhagia?
- What is the historical and forecasted Metrorrhagia patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
- What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current treatment guidelines and treatment options, in addition to approved therapies for Metrorrhagia in the US, Europe, and Japan?
- What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Metrorrhagia therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Metrorrhagia and its status, along with the challenges faced?
Reasons to Buy
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Metrorrhagia market
- Organize sales and marketing efforts by identifying the best opportunities for Metrorrhagia in the US, Europe (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
- Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors
Frequently Asked Questions
1. Key Insights
2. Executive Summary of Metrorrhagia
3. Competitive Intelligence Analysis for Metrorrhagia
4. Metrorrhagia: Market Overview at a Glance
4.1. Metrorrhagia Total Market Share (%) Distribution in 2019
4.2. Metrorrhagia Total Market Share (%) Distribution in 2032
5. Metrorrhagia: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Metrorrhagia Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Metrorrhagia Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Metrorrhagia Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Metrorrhagia Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. Metrorrhagia Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. Metrorrhagia Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. Metrorrhagia Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Metrorrhagia Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. Metrorrhagia Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Metrorrhagia Treatment and Management
8.2. Metrorrhagia Treatment Algorithm
9. Metrorrhagia Unmet Needs
10. Key Endpoints of Metrorrhagia Treatment
11. Metrorrhagia Marketed Products
11.1. List of Metrorrhagia Marketed Drugs in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Metrorrhagia Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Metrorrhagia: Seven Major Market Analysis
13.1. Key Findings
13.2. Metrorrhagia Market Size in 7MM
13.3. Metrorrhagia Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Metrorrhagia Total Market Size in the United States
15.1.2. Metrorrhagia Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Metrorrhagia Total Market Size in Germany
15.3.2. Metrorrhagia Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Metrorrhagia Total Market Size in France
15.4.2. Metrorrhagia Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Metrorrhagia Total Market Size in Italy
15.5.2. Metrorrhagia Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Metrorrhagia Total Market Size in Spain
15.6.2. Metrorrhagia Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Metrorrhagia Total Market Size in the United Kingdom
15.7.2. Metrorrhagia Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Metrorrhagia Total Market Size in Japan
15.8.3. Metrorrhagia Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Metrorrhagia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Table
Table 1: 7MM Metrorrhagia Epidemiology (2019-2032)
Table 2: 7MM Metrorrhagia Diagnosed and Treatable Cases (2019-2032)
Table 3: Metrorrhagia Epidemiology in the United States (2019-2032)
Table 4: Metrorrhagia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Metrorrhagia Epidemiology in Germany (2019-2032)
Table 6: Metrorrhagia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Metrorrhagia Epidemiology in France (2019-2032)
Table 8: Metrorrhagia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Metrorrhagia Epidemiology in Italy (2019-2032)
Table 10: Metrorrhagia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Metrorrhagia Epidemiology in Spain (2019-2032)
Table 12: Metrorrhagia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Metrorrhagia Epidemiology in the UK (2019-2032)
Table 14: Metrorrhagia Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: Metrorrhagia Epidemiology in Japan (2019-2032)
Table 16: Metrorrhagia Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: 7MM Metrorrhagia Epidemiology (2019-2032)
Figure 2: 7MM Metrorrhagia Diagnosed and Treatable Cases (2019-2032)
Figure 3: Metrorrhagia Epidemiology in the United States (2019-2032)
Figure 4: Metrorrhagia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: Metrorrhagia Epidemiology in Germany (2019-2032)
Figure 6: Metrorrhagia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: Metrorrhagia Epidemiology in France (2019-2032)
Figure 8: Metrorrhagia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: Metrorrhagia Epidemiology in Italy (2019-2032)
Figure 10: Metrorrhagia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: Metrorrhagia Epidemiology in Spain (2019-2032)
Figure 12: Metrorrhagia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: Metrorrhagia Epidemiology in the UK (2019-2032)
Figure 14: Metrorrhagia Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: Metrorrhagia Epidemiology in Japan (2019-2032)
Figure 16: Metrorrhagia Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary